指南与共识重症综合管理与镇静镇痛消化、代谢与肾脏急症

2025年中国侵袭性真菌监测网(CHIF-NET)念珠菌感染监测与控制指南

The 2025 guidance on the surveillance and control of Candida infections: Recommendations from the China invasive fungal surveillance net (CHIF-NET) study group.
指南 / 共识 · J Microbiol Immunol Infect · 2026-03-07
一句话结论CHIF-NET研究组基于GRADE框架制定念珠菌感染监测与控制指南,覆盖诊断策略、抗真菌治疗及感染防控,目标人群包括临床医生、微生物学家、感染控制人员与政策制定者。

念珠菌感染是全球常见真菌病,在免疫抑制和危重患者中致残致死率显著,抗真菌耐药的出现与传播构成公共卫生威胁。CHIF-NET研究组组织感染病学、临床微生物学、药理学、感染控制和指南方法学多学科专家,按GRADE框架系统评价证据后制定本临床实践指南。推荐强度分为强推荐与条件(弱)推荐,证据确定性由高到低分级。指南就念珠菌感染的诊断策略、抗真菌治疗和感染预防控制措施提出推荐,整合全球证据与国内临床经验,旨在优化临床决策、改进抗真菌药物管理和加强感染控制。

要点

  • 指南由CHIF-NET研究组多学科团队按GRADE框架制定,推荐强度分为强推荐与条件(弱)推荐,证据确定性由高到低分级。
  • 目标用户包括临床医生、微生物学家、感染控制人员与政策制定者,涵盖诊断策略、抗真菌治疗和感染预防控制三方面。
  • 念珠菌感染在免疫抑制和危重患者中致残致死率显著,抗真菌耐药的出现与传播构成全球公共卫生威胁。
  • 指南整合全球证据与国内临床经验,旨在支持优化临床决策、改进抗真菌药物管理并加强感染控制策略。

适用人群与场景

  • 免疫抑制和危重患者是念珠菌感染的高危人群,疾病致残致死率显著。
  • 指南目标用户包括临床医生、微生物学家、感染控制人员与政策制定者。

处置流程与药物剂量

  • 指南就念珠菌感染的诊断策略、抗真菌治疗和感染预防控制措施提出推荐,推荐强度分为强推荐与条件(弱)推荐,证据确定性由高到低分级。

研究设计与关键结果

  • CHIF-NET研究组组织感染病学、临床微生物学、药理学、感染控制和指南方法学多学科专家,按GRADE框架制定本临床实践指南。
  • 临床问题基于当前实践的优先问题或不确定性领域提出,经系统评价和最佳证据综合后形成相应推荐。
  • 推荐强度分为强推荐与条件(弱)推荐,证据确定性由高到低分级。
  • 指南提供念珠菌感染的诊断策略、抗真菌治疗和感染预防控制措施推荐,整合全球证据与国内临床经验。

证据类型、等级与局限

  • 证据类型:临床实践指南,采用GRADE框架,推荐强度分为强推荐与条件(弱)推荐,证据确定性由高到低分级。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 指南旨在支持优化临床决策、改进抗真菌药物管理并加强感染控制策略,以应对念珠菌感染带来的日益严峻挑战。

指南或共识出处

  • 2025年中国侵袭性真菌监测网(CHIF-NET)研究组念珠菌感染监测与控制指南(J Microbiol Immunol Infect)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Candida infections are among the most common fungal diseases worldwide and are associated with notable morbidity and mortality, particularly in immunocompromised and critically ill patients. Moreover, the emergence and spread of antifungal resistance pose an increasing threat to global public health. Therefore, evidence-based recommendations are urgently needed to guide the surveillance and control of Candida infections. A multidisciplinary guidance development group comprising experts of infectious diseases, clinical microbiology, pharmacology, infection control, and guideline methodology jointly developed the present clinical practice guidance. The process followed internationally recognized grading of recommendations, assessment, development and evaluation (GRADE) framework. Clinical questions were formulated based on priority issues or areas of uncertainty in current practice, and corresponding recommendations were developed after systematic review and synthesis of the best available evidence. The strength of recommendations was classified as strong or conditional (weak), and the certainty of evidence was graded from high to low. The guidance provides recommendations on diagnostic strategies, antifungal therapy, and infection prevention and control measures for Candida infections, integrating both global evidence and national clinical experience. The target users include clinicians, microbiologists, infection control practitioners, and policymakers involved in the management of fungal diseases. The guidance aims to support optimized clinical decision-making, improve antifungal stewardship, and strengthen infection control strategies to address the growing challenge posed by Candida infections.

来源:J Microbiol Immunol Infect,查看原文。版权归原作者所有。

参考来源

  1. Xiao M, Zhang L, Wang H, et al. The 2025 guidance on the surveillance and control of Candida infections: Recommendations from the China invasive fungal surveillance net (CHIF-NET) study group. J Microbiol Immunol Infect. 2026. PMID: 41916807. doi:10.1016/j.jmii.2026.03.003

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。